Fresh plans to expand the highly successful Stevenage Bioscience Catalyst (SBC) campus have recently been unveiled. The growth strategy is set to create 5,000 new jobs.
The new campus, which will be one of the largest of its kind in the UK and Europe, will be built alongside SBC and its 40+ occupier companies, the Cell and Gene Therapy Catapult and GSK’s existing global R & D centre.
UBS Asset Management and Reef Group, experienced life science investors and developers are expected to deliver up to £900 million of new investment alongside an estimated 1.4 million square feet of laboratory and office facilities, providing space for up to 5,000 new jobs.
UBS Asset Management and Reef are already delivering major life science projects across the world with a gross development value in excess of £5 billion. UBS and Reef are set to buy 33 acres of land from GSK to develop the new campus. Construction of the new campus will start in 2023 and subject to planning; some components of the site will be open for business by 2025.
The Stevenage campus is a leading location for life science companies to develop and commercialise cutting edge therapeutics. It is a unique location that brings together major multinationals, the Cell and Gene Therapy Catapult Manufacturing Centre and Stevenage Bioscience Catalyst’s 40+ biotech companies.
The new campus will add much-needed laboratory space and facilities for new companies to locate to the Stevenage campus and further strengthen the UK life science ecosystem.
For full story visit
